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Abstract: Obesity is a worldwide epidemic with multiple obesity-associated health problems 
including type 2 diabetes, hypertension, and cardiovascular disease. Adipose tissue serves 
as a fuel storage depot, but also plays a pivotal role in homeostasis of energy expenditure, 
appetite regulation, glucose regulation, and immunity. Both genetics and environment play 
important roles in adipose tissue function and dysfunction. Obesity represents an abnormal 
accumulation of adipose tissue resulting from chronic overnutrition and reduced physical 
activity. The  nature  of  this  increased  accumulation  of  fat  tissue,  whether  hyperplasia  or 
hypertrophy, local or ectopic, is associated with deleterious perturbations including excess 
fatty acid secretion, increased production of inflammatory cytokines, and abnormal adipocyte 
hormone signaling resulting in insulin resistance. In the setting of obesity, insulin resistance 
and chronic inflammation is postulated to play a role in development of type 2 diabetes and 
other  obesity-related  comorbidities  including  obstructive  sleep  apnea,  hepatic  steatosis, 
polycystic ovarian syndrome, hypertension and cardiovascular disease. Although the exact 
mechanism of these relationships are complex and not completely understood, the ability to 
store and limit fatty acid deposition to adipose tissue is a common component to remaining 
insulin sensitive, controlling the inflammatory cascade and reducing the risk of developing 
obesity-related comorbidities.
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Introduction
The epidemic of obesity is worldwide – the World Health Organization statistics from 
2005 demonstrated that 400 million people were obese in the world, with a projected 
increase to 700 million by 2015.1 In the USA, the current prevalence of obesity for 
adult men is 32.2% and for adult women 35.5%.2 The etiology for the increased rates of 
obesity has been related to worsening lifestyle, with overnutrition and lack of   physical 
activity. This increase in obesity is a prelude to multiple   obesity-associated health 
problems including type 2 diabetes mellitus (DM), cardiovascular disease (CVD), and 
hypertension (HTN), and often these diseases occur together. The term   “metabolic 
  syndrome” has been used to characterize this clustering of diseases, although the 
  definition of metabolic syndrome has sparked much debate. The strict definition 
of metabolic syndrome is having 3 or more of the following   abnormalities: waist 
  circumference greater than 102 cm in men and 88 cm in women; serum   triglyceride 
level of 150 mg/dL or higher; high-density lipoprotein (HDL) cholesterol level less 
than 40 mg/dL in men and 50 mg/dL in women; blood pressure of 130/85 mmHg or Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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higher; fasting glucose level of 110 mg/dL or higher.3 The 
age at which obesity-related comorbidities begin is unclear. 
Studies have demonstrated higher rates of morbidity and 
mortality from CVD, stroke, and colorectal cancer in adults 
with a history of adolescent-onset obesity vs those who 
were not obese as adolescents.4 Whether this worsening of 
disease is related solely to the duration of obesity, or whether 
the underlying changes in metabolism and inflammation 
that characterizes this constellation of comorbidities is the 
primary issue, is unknown. Therefore, understanding the 
role of the fat tissue in hormone secretion, inflammation, 
appetite stimulation, and the pathophysiology of obesity-
related comorbidities will be of key importance in developing 
treatment and prevention strategies.
Discussion
Physiological role of adipose tissue  
in the body
Adipose tissue serves as the major storage site for fuel, 
  primarily in the form of triglycerides. Mammalian adipose 
tissue can be divided into brown adipose tissue and white 
adipose tissue (WAT) with the majority of fat in humans 
occurring as WAT. Brown adipose tissue is important for 
regulating heat and non-shivering thermogenesis, and is seen 
predominately in young and/or hibernating mammals. WAT 
serves several roles including heat insulation, mechanical 
cushioning, and fuel storage.5 Adipose tissue also acts as a 
buffer for energy imbalances in the setting of energy excess 
and storage.
The bulk of adipose tissue is made up of lipid filled 
adipocytes held together by a framework of collagen fibers. 
Other cells found within the fat include stromal-vascular 
cells, leukocytes, macrophages and pre-adipocytes.6–8 The 
white adipose cells have limited vascularity, with blood flow 
varying based on body weight and nutritional status. In the 
setting of fasting, blood flow increases to the WAT.
The size of the adipose tissue mass is a function of 
both adipocyte number and size.6 Adipocyte number is 
controlled by apoptosis/necrosis and through development 
and differentiation of progenitor cells, preadipocytes. An 
increase in adipocyte mass can occur with differentiation 
of pre-  adipocytes, as well as with increased lipid deposition 
within the adipocyte.7,8 In humans, there are 2 periods of 
hyperplastic growth, including the 3rd trimester of pregnancy 
and early in puberty. However, hyperplastic growth can occur 
in adulthood. When adipocytes reach a critical size, precursor 
cells are stimulated to differentiate which results in increase 
in adipocyte number. Once new adipocytes are formed, 
which can occur in the setting of long term   overfeeding, 
they remain for life. The mechanism for these signals is 
not well defined and may be in part genetically determined. 
In addition, in WAT there are differences in the rates of 
apoptosis and number and differentiation of progenitor cells 
between subcutaneous fat depots and visceral fat depots as 
well as differences in responses to certain stimuli such as 
tumor necrosis factor-alpha (TNF-α) on apoptosis and per-
oxisome proliferator-activated receptor-gamma (PPAR-γ) 
on proliferation.9 Obesity due to hyperplastic cell growth 
is felt to be more benign with regards to development of 
metabolic derangements and inflammation than adipocyte 
hypertrophy in which the fat cell has decreased ability to 
store triglycerides.10
In addition to energy storage, adipose tissue plays an 
active role in many homeostatic processes including energy 
expenditure, appetite regulation, and glucose regulation. In 
addition, fat tissue is critical for thyroid function, immune 
response, bone health maintenance, reproduction, and blood 
clotting. These processes are regulated by a variety of 
  hormone pathways and interactions. The adipose tissue is 
an active endocrine organ secreting free fatty acids,   leptin, 
  adiponectin, adipsin, complement factor 3, interlukin-6 
(IL-6), TNF-α, angiotensinogen, and plasminogen   activation 
inhibitor-1 (PAI-1), among others. Abnormal signaling, 
  deficiency of, or resistance to these hormones have been 
shown to have deleterious effects.11
Genetics of obesity
The etiology for the increasing incidence of obesity is 
  primarily lifestyle-related overnutrition and reduced physi-
cal activity, but susceptibility to obesity is complicated 
and involves environment influenced by genetics. Studies 
of twins, adoptees, and families all suggest the existence 
of genetic factors in human obesity.12,13 The heritability of 
obesity estimated from twin studies is high, ranging between 
0.6 and 0.9, with only slightly lower values in twins raised 
apart compared with those raised together.13 Similarly, in 
adoptees, the body mass index (BMI) correlates with that 
of their biologic parents rather than that of their adoptive 
parents.13 Wardle et al14 examining 5000 pairs of twins age 8 
to 11, revealed that genes were responsible for 77% of the dif-
ference in BMI and waist circumference, and environmental 
influences accounted for 23% of the differences.
Genetic influence of obesity is related to 2 primary 
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energy requirements, and 2. presence of a normal drive to 
eat despite low energy requirements. Appetite and the drive 
to eat may be impacted by several genetically programmed 
  metabolic pathways and this is demonstrated in the specific 
but rare syndromes of Prader-Willi and leptin deficiency.15 
Genes may help create the energy imbalance that leads to 
obesity. In addition to the heritability of weight, metabolic 
rate, thermic response to food, and spontaneous physical 
activity are to some extent heritable.16 These relationships 
were illustrated in a study of overfeeding in identical twins.17 
With respect to body weight, percentage of fat, fat mass, and 
estimated subcutaneous fat, there was approximately three 
times more variance among pairs than within pairs, indicating 
both current weight status and the metabolic processes under-
lying weight gain have a strong inherited component. The 
central nervous system provides the feedback control system 
for integration of energy expenditure and for   digestion, 
absorption, transport, and storage of nutrients, and mobiliza-
tion and utilization of fuels. Signals regarding alterations in 
fuel utilization are tightly regulated and come primarily from 
adipocytes and from the gastrointestinal tract.
In addition, obesity is one of the leading risk factors 
for the development of DM and most people with DM 
are overweight or obese. Yet the genetics of DM are also 
not well defined except for a few of the rarer forms of 
inherited diabetes such as maturity onset of diabetes of the 
young (MODY). Furthermore, the link between these 2 
complex diseases of fuel metabolism has eluted genome-
wide searches and associations. In a recent review article, 
De Silva et al18 summarizes the known 100 common gene 
variants for predisposition to Type 2 DM, obesity, insulin 
resistance, beta cell function, and elevated cholesterol and 
their unique and variable impact on fuel metabolism. To 
identify specific gene defects, Bougnères describes the need 
to phenotype obesity and DM in order to better identify small 
genetic variants, as the expression of polymorphisms may 
be related to environmental changes or triggers that lead to 
susceptibility to DM and obesity as opposed to monogenic 
abnormalities.19 In this regard, environment plays a key 
role in genetic expression, minimizing the ability to target 
specific genes for therapy.
Pathophysiology of increasing adiposity
When a person is in positive balance, energy is stored 
in subcutaneous and visceral fat. Obesity is an excess 
of body fat resulting from an imbalance between energy 
intake and energy expenditure. Although this statement 
simplifies the process of obesity, it fails to account for the 
complicated interaction of variables such as growth hor-
mone, reproductive hormone secretion, and the feedback 
between energy intake and expenditure, physical activity 
responses, age, and genetics, as well as psychological 
issues that may predict eating habits. In addition, it fails 
to delineate the negative downstream consequences trig-
gered by the body’s inability to accommodate the chronic 
overfed state. Chronic   overnutrition promotes a vicious 
cycle of   proinflammatory cytokine secretion, suppression 
of anti-inflammatory release and macrophage infiltration, 
leading to metabolic   derangements such as insulin resis-
tance and diabetes.
Fatty acids
One of the negative consequences of chronic overfeeding is 
elevated levels of free fatty acids. Elevated fatty acids are 
commonly seen in obesity and DM and lead to diminished 
whole body glucose utilization and diminished skeletal 
muscle and cardiac muscle glucose utilization.20 In addition, 
increased levels of circulating fatty acids are inhibitory to 
beta cells and lead to reduced beta cell function with dimin-
ished insulin secretion.21
In the setting of increased free fatty acids, the adipose 
tissue attempts to “keep up” with the fatty acid influx by 
increasing storage of this excess fuel with both hypertrophy 
and hyperplasia of the adipose mass. With hypertrophy, 
increased rates of hypoxia and cell death are seen. The 
etiology for cellular hypoxia is unclear but is thought to 
be related to overgrowth of adipose tissue in the setting of 
failed compensatory angiogenesis as noted by failure of 
vascular endothelial growth factor (VEGF) expression to 
increase, leading to decrease adipose tissue blood flow and 
increased vasoconstriction related to increase expression of 
angiotensin II.22 This is supported by the reduced adipocyte 
blood flow seen in obese, nondiabetic and DM subjects and 
the increased macrophages seen in the fat tissue of obese 
individuals as a result of increased free fatty acids.23,24 
Mechanistically, in the adipose tissue, induction of innate 
immune receptors such as Toll-like receptor (TLR) 4 and 
TLR-2 by the increased free fatty acids can lead to activation 
of IκB/nuclear factor κ-  light-chain-enhancer of activated 
B cells (NFκB) system and Jun N-terminal kinase (JNK), 
resulting in an inflammatory response.25,26 The subsequent 
inflammatory response by the adipose tissue stimulates 
secretion of other pro-inflammatory cytokines, locally and 
systemically.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Negative consequences of increasing 
adiposity
Oxidative stress
Oxidative stress is due to an imbalance between the ability of 
a biological system to detoxify and the production of reactive 
oxygen species (ROS) such as peroxides and free radicals. 
This imbalance can lead to cell damage and apoptosis. 
  Evidence suggests that obesity may induce systemic oxidative 
stress via oxidative stress in the accumulated adipose tissue, 
leading to derangements in adipocytokines secretion.27 In a 
series of elegant experiments examining the relationship of 
obesity and oxidative stress, Furukawa et al27 made the fol-
lowing observations: 1. in obese, nondiabetic humans, lipid 
peroxidation, a marker of oxidative stress, as measured by 
plasma thiobarituric acid reactive substance (TBARS) and 
urinary 8-epi-prostaglandin-F2α (8-epi-PGF2α), correlated 
with BMI and waist circumference, and inversely correlated 
with adiponectin; 2. in obese mice models including KKAy, 
DIO, and db/db mice, lipid peroxidation in plasma as well as 
in WAT was increased; 3. in KKAy mice, mRNA expression 
was lower for adiponectin and PPARγ in WAT and higher for 
expression of proinflammatory markers, PAI-1 and TNF-α, 
prior to the onset of diabetes, when compared to controls; 
4. in mice, augmentation of NADPH oxidase, a principal 
source of ROS, occurred in WAT but not in liver or skeletal 
muscle; and 5. in cultured adipocytes, elevated ROS levels 
were seen in differentiation of 3T3-L1 pre-adipocytes into 
adipocytes, indicating a role for fat accumulation in ROS 
production. They concluded that the obese state is charac-
terized by oxidative stress. Oxidative stress in humans has 
been found to play a role in the development of diabetes, 
hypertension, and vascular disease and may be a mechanistic 
link between obesity and the metabolic syndrome.28–30
Increased inflammatory markers
Inflammation appears to be one of the key but complex 
triggers linked to the metabolic derangements of obesity. 
Obesity itself represents a chronic inflammatory state, as 
noted by increased levels of proinflammatory cytokines 
including IL-1, IL-6, and TNF-α, with a downstream 
cascade that can stimulate liver production of C-reactive 
protein (CRP) and other cytokine release.The inflammatory 
response seen locally at the adipose tissue level also includes 
macrophage infiltration and resistance to hormones such as 
leptin, and systemically by increased levels of CRP, PAI-1 
and fibrinogen, and tissue specific hormone activity such 
as overexpression of 11β-hydroxysteroid dehydrogenase 
(11β-HSD).31 In conjunction with the concept of obesity 
being a state of chronic inflammation potentiating the 
development of insulin resistance and HTN, interest in 
defining the mechanistic relationship between impaired 
glucose-insulin metabolism and obesity, and the potential 
impact of interventions such as physical activity, has been 
highlighted by several studies.32,33
Dysregulated adipocytes hormone signaling
Adipose tissue plays a significant role in hormone   secretion 
and regulation to maintain metabolic and immune   function.34,35 
In the past decade, anti-inflammatory adipokines (including 
leptin and adiponectin), along with   proinflammatory adipo-
cytokines (including TNF-α, IL-6, resistin, and 11β-HSD 
and many others), have all received tremendous attention 
for their potential role in obesity, glucose homeostasis, 
insulin   resistance, and atherosclerosis,34,35 each appearing to 
play variable roles, locally and systemically, in a redundant 
system.
Adiponectin, a 244 amino acid peptide solely produced 
and secreted by adipose tissue, has been reported to 
improve insulin sensitivity and possibly reduce the risk of 
DM.36,37 Unlike other adipose tissue-derived peptides that 
are elevated in obesity, adiponectin levels are decreased in 
obese individuals with insulin resistance, and higher levels of 
  adiponectin are associated with lower risk of DM in older men 
and women.36,38 Thus, the lower adiponectin levels in obese 
individuals with larger adiposity are paradoxical   suggesting 
that in obese individuals, the adiponectin gene may be down 
regulated. To complicate this further, adiponectin is secreted 
differentially within the visceral and subcutaneous fat. In a 
recent review, Samaras et al39 demonstrated depot-specific 
differences in expression of DM predictors: visceral adipose 
tissue (VAT) expressed higher levels of complement C3; 
subcutaneous adipose tissue (SAT) expressed higher levels 
of retinol-binding protein-4 (RBP4), adiponectin, and leptin. 
The VAT in DM, expressed higher levels of inflammatory 
adipokines. Finally, it is well known that interventions 
that reduce percent adipose mass, weight loss, and aerobic 
exercise independently increase adiponectin levels with a 
concomitant improvement in insulin sensitivity. However, 
the direct role of adiponectin on insulin resistance continues 
to be examined and may be site specific.37,39–40
Leptin, also produced by the adipocytes, circulates at   levels 
proportionate to levels of body fat. It binds to   receptors in the 
hypothalamus, activating signals to inhibit food intake and 
increase energy expenditure. Leptin affects other   hormones, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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both anorectic and orexigenic. In muscle, leptin stimulates 
free fatty acid oxidation and attenuates   insulin-mediated 
anti-oxidative effects. In adipose tissue, leptin inhibits insulin 
binding, insulin-mediated glucose transport, lipogenesis, and 
glycogen synthase activity. In addition, leptin plays a role 
in areas other than fuel metabolism including fetal growth, 
puberty, hematopoiesis, and thermogenesis.41 Congenital 
leptin deficiency is rare and it appears that the typical state 
of obesity in humans is more likely to be related to leptin 
resistance rather than deficiency.42
Other hormones secreted by the adipose tissue include 
resistin, and primarily by the VAT, visfatin, omentin, and 
vaspin, are thought to play a role in insulin resistance 
although their exact functions are unclear. Resistin is elevated 
in obesity and DM, but it is not thought to play a primary 
role in the development of insulin resistance.
insulin resistance
Obese adults demonstrate reduced glucose disposal, pri-
marily at the level of skeletal muscle (peripheral insulin 
resistance), as well as impairment in insulin action on non-
esterified fatty acid oxidation leading to insulin resistance 
and abnormal lipolysis.43,44 Yet it is unclear whether these 
abnormalities occur in the setting of acute vs chronic obe-
sity. Polonsky et al45 examined obese, nondiabetic adults 
and found that insulin secretion rates were significantly 
higher in the obese group when compared to the normal 
weight group.   Furthermore, there was no difference in 
insulin clearance or hepatic insulin extraction between the 
groups. There was a diminished hepatic insulin extraction 
noted in a subset of the obese group that demonstrated 
greater degree of   hyperinsulinemia. To examine this fur-
ther, Monti et al46 examined obese children with normoin-
sulinaemia to   characterize early metabolic derangement, 
and found   peripheral insulin resistance when compared 
to normal weight children, but no significant differences 
in   nonesterified fatty acids response to insulin infusion. 
Le Stunff et al47 found that the earliest abnormality in 
glucose metabolism in obese children (those with short 
duration of obesity) was an abnormal insulin response to a 
meal stimuli, and that maximal glucose uptake decreased 
with obesity duration and age. Although evidence exists that 
whole body, skeletal muscle, and hepatic insulin resistance 
improves as does hyperglycemia, hyperlipidemia, and HTN 
with the loss of excess body weight, the mediators of the 
relationship between glucose dysregulation and weight loss 
remain unclear.48 The mechanism for obesity-induced insulin 
resistance is related to overproduction of proinflammatory 
cytokines and hormones that directly and indirectly induce 
insulin resistance.49,50 Retinol-binding protein-4, secreted 
by the adipose tissue, induces insulin resistance via reduced 
phosphatidylinosital-3-OH kinase signaling in the muscle 
and increase expression of phosphenolpyruvate carboxyki-
nase in the liver, along with diminished adiponectin and 
PPAR-α activity typical for obesity.51 Other factors, both 
systemically and locally, including TNF-α, IL-6, monocyte 
chemoattractant protein-1, and macrophage products play a 
role in development of insulin resistance in addition to, and 
through, their inflammatory properties. In this regard, Iozzo10 
has demonstrated that, although insulin resistance does 
improve, regional adipose-specific insulin resistance and 
hypoperfusion does not improve with weight loss, consistent 
with the hypothesis of irreversible GLUT-4 translocation 
defects in the adipose tissue, and thus providing a molecular 
link between obesity and glucose/fat dysregulation. This irre-
versible change at the level of the fat could be problematic 
for weight maintenance or regain. So, it appears that one of 
the earliest negative effects of obesity is the development 
of insulin resistance.
Metabolic fat distribution
Total and abdominal adiposity increase the risk for CVD 
and mortality among women. Increases in total body fat, 
VAT, and fat deposition in the muscle occur with age and 
are   associated with insulin resistance, dyslipidemia, and 
risk for DM and CVD. Subcutaneous fat, when compared to 
  visceral fat, is a more active storage depot, is more responsive 
to the anabolic action of insulin, and demonstrates a greater 
readiness for proliferation and expansion.9–11 Visceral fat is 
less sensitive to insulin, which provides a ready depot of 
energy for local organs and less ability for expansion with 
fuel storage.10
Abdominal or central obesity includes fat   surrounding 
the heart and other organs, intestinal mesentery, and ret-
roperitoneum and is believed to be responsible for CVD, 
possibly related to drainage into the portal system of the 
liver, exaggerating the metabolic response. However, the 
relationship between CVD and VAT is not straightforward, 
as racial and ethnic differences exist. African Americans 
have greater insulin resistance with less visceral fat when 
compared to Caucasians.52
Observations that DM appears to resolve quickly after 
Roux-en-Y gastric bypass (RYGB) may be explained by 
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resonance imaging (MRI) to assess VAT loss as a result of 
bariatric surgery, Busetto et al53 concluded that during the 
initial rapid weight loss period (ie, initial 6 month period), 
a   preferential mobilization of visceral fat, as compared with 
total and subcutaneous adipose tissue, can occur and this 
may explain in part the metabolic improvements that can 
occur early after bariatric surgery with remission of DM, 
improvement in insulin resistance, blood pressure, and 
hyperlipidemia. It is postulated that these changes occur due 
to changes in incretin secretion and interaction with adipose 
tissue brought about by the bypass of the hormonally active 
small bowel. As with total body fat, the distribution of body 
fat between visceral and subcutaneous compartments also 
has important genetic determinants.12
As a component of central adiposity, altered muscle 
composition, suggestive of increased ectopic fat content, 
is an important independent marker of insulin resistance 
in   obesity.54 In this regard, the ability of the adipose tissue 
to expand and contain fatty acid deposition is important to 
  maintain insulin sensitivity and reduce the inflammatory 
response. When the adipocytes can no longer   accommodate 
the excess fuel delivered, overflow from adipocytes to 
other areas including skeletal muscle, liver, and heart 
occurs. This ectopic fat deposition can result in deleterious 
effects   including free radical formation during oxidative 
  phosphorylation, intramyocellular triglyceride   accumulation, 
and the production of toxic lipid metabolites such as   fatty-acyl 
CoAs, ceramides and others that can cause   oxidative   damage 
and interfere with insulin signaling at these ectopic sites. 
Within the fat itself, local production of free radicals 
  potentiates lipotoxicity and insulin resistance and provides 
the trigger for other detrimental hormone cascades.10
Physical inactivity
When we discuss the negative consequences of obesity on glu-
cose and lipid regulation, inflammation, and body fat distribu-
tion, we must consider the role of physical   inactivity in both 
development of obesity, and as an independent mediator of 
metabolic derangements.55 Crespo et al56 found that physical 
activity protected against all-cause mortality, independent of 
body weight. With regard to ectopic fat deposition, Perseghin 
et al57 found that habitual physical activity was associated 
with reduced intrahepatic fat content and Goodpaster54 
demonstrated that ectopic fat in the thigh muscle correlated 
to inactivity and insulin resistance. Physical activity has 
been found to improve insulin resistance and reduce the risk 
of development of DM and promote lipid oxidation.8,10,57 
The precise mechanism for these actions is unclear, but it does 
appear that the majority of benefits of exercise are obtained 
via its impact on metabolic factors rather than weight loss 
associated with increase caloric expenditure. Thus, the meta-
bolic derangements seen in the setting of inactivity, and the 
metabolic improvements brought about by physical activity, 
provide insight into the pathophysiology of obesity.
Development of obesity comorbidities  
as characterized by insulin resistance  
and increase inflammation
Type 2 diabetes mellitus
In the pathology of DM, inflammation appears to play 
a role in disease development and progression. Chronic 
inflammation in adipose tissue, liver, and skeletal muscle 
provoke insulin resistance and at the islet, provokes beta cell 
dysfunction. It is the combination of insulin resistance and 
beta cell dysfunction that characterizes DM. Various markers 
of inflammation have been associated with DM including 
CRP, IL-6, MCP-1, IL-8, and PAI-1. The ability of these 
inflammatory markers to predict DM appears to be unique 
to the timing of DM development, with some markers more 
predictive in impaired glucose tolerance and others in frank 
diabetes.48,58,59 In addition, in the setting of diabetes, multiple 
other comorbidities are more commonly seen including OSA, 
hepatic steatosis, HTN, hyperlipidemia, and CAD, indicating 
a possible common pathway.
Obstructive sleep apnea
Obstructive sleep apnea (OSA) is commonly seen in the 
  setting of obesity and DM. It is characterized by sleep 
  disordered breathing, with pauses in breathing that result 
in arousal or desaturation. Sleep disturbance is linked to 
higher inflammatory biomarkers such as CRP, IL-6, key 
proinflammatory cytokines in insulin resistance, and DM.60 
Adipose hormone changes have also been demonstrated 
in this setting, including a drop in leptin, increased insulin 
levels, and a decrease in insulin sensitivity. The etiology for 
this is unclear, but felt to be related to intermittent hypoxemia 
that may potentiate the inflammatory cascade, triggering 
systemic inflammation.60,61 In this regard, studies demonstrate 
improved glucose control and reduced insulin resistance with 
treatment of OSA.
Hepatic steatosis
This condition is highly correlated with DM, obesity, 
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fatty liver   disease (NAFLD) is a common manifestation of 
hepatic  insulin resistance. One study showed that NAFLD 
is   associated with insulin resistance even in patients with 
  normal glucose tolerance tests. Adipose tissue lipolytic 
  activity is increased in NAFLD and results in an increase 
in the rate of fatty acid release into plasma throughout 
the day. This continual excess in fatty acid flux supports 
the   hypothesis that adipose insulin resistance is involved 
in the pathogenesis of hepatic steatosis and contributes to 
the metabolic complications associated with NAFLD.62 In 
addition, obesity leads to infiltration of adipose tissue by 
macrophages that produce cytokines such as IL-6, which 
contribute to insulin resistance and promote a downstream 
effect of increased hepatic CRP production.
Polycystic ovarian disease
Polycystic ovarian disease (PCOS) is commonly accompa-
nied by hyperandrogenism and hyperinsulinemia. Although 
the exact mechanism for this relationship is unclear, it is 
  postulated that high circulating levels of insulin play a role 
in ovarian cyst development due to the anabolic effect of 
insulin at the IGF receptors found on the ovaries. Up to 30% 
of women with polycystic ovarian disease are overweight/
obese. Obesity can worsen the picture of PCOS by   increasing 
insulin resistance, DM, and metabolic syndrome, but the 
increased degree of obesity itself has only a modest impact 
on disease development.63
Hypertension
When examining the relationship of obesity to HTN, elevated 
blood pressure occurred more than 9 times more frequently 
in the obese group.64 The incidence of HTN is two fold higher 
in subjects with DM when compared to subjects   without.65 The 
exact mechanism for this relationship is unclear.   Activation of 
the sympathetic nervous system leading to sodium   retention 
and resetting of volume status appears to be an early change in 
the setting of obesity. Plasma renin activity, angiotensinogen, 
angiotensin II, and aldosterone are increased, and leptin, 
endothelin 1, and other neuropeptides also play a role.66 
Endothelin 1, an   endothelium-derived   vasoconstrictor, is 
associated with increased vascular tone, development of 
HTN, and atherosclerosis. In linking endothelin 1 to the 
metabolic syndrome, hyperglycemia increases endothelin 1 
expression in cell culture through protein kinase C (PKC);67 
and in endothelial cells, insulin increases endothelin 1,  68 
indicating a mechanistic   relationship between obesity, insulin 
resistance, and HTN.
Hyperinsulinemia appears to play a role in the development 
of HTN; possibly related to changes in angiotensin II and 
sodium retention in obese subjects.69
Hyperlipidemia
The classic dyslipidemic pattern of the metabolic syndrome 
is characterized by elevated serum low-density lipoprotein-
cholesterol and triglycerides and reduced high-density 
lipoproteins. This pattern is associated with enhanced 
tendency to LDL oxidation, and a reduction in the ability 
of HDL to promote cellular cholesterol efflux. Central fat 
distribution, possibly through its impact on insulin levels, 
may be the mediating variable between obesity and lipids. 
Increased free fatty acids, produced by lipolysis by the 
visceral adipocytes, and hyperinsulinemia, promotes hepatic 
triglyceride and LDL-cholesterol synthesis.70,71 Weight 
reduction improves this profile.
Cardiovascular disease
Obesity correlates strongly with traditional risk factors 
of CAD including DM, HTN, hyperlipidemia, and OSA. 
Unifying these comorbidities is the back drop of chronic 
inflammation. Obesity, and central obesity in particular, 
is associated with increased inflammatory markers such as 
CRP, IL-6, and PAI-1 and there may be genetic susceptibility 
to oxidative stress.72–74 This inflammatory state promotes 
increased oxidative stress and endothelial dysfunction that in 
turn promotes atherosclerosis, made worse by hyperglycemia. 
Endothelial dysfunction is characterized by diminished 
production of nitric oxide and other vasoprotective factors 
and/or increased production of vasoconstrictors and proin-
flammatory factors such as angiotensin II, endothelin 1 and 
ROS.75 The damaged endothelial surface is a stimulant for 
mononuclear cell infiltration for repair, and the abnormal 
lipid oxidation results in development of fatty streaks and 
vulnerable plaques.76 In the setting of DM, an early marker 
of inflammation is the release of monocyte chemoattractant 
protein (MCP)-1 and macrophage migration inhibition factor 
(MIF) in vascular endothelium and adipose tissue which 
potentiates vascular disease.74,76–78
The healthy obese
Although obesity is linked to many comorbidities as described 
above, it is most likely not a direct causal relationship. In 
this regard, Khittle et al79 found that approximately 20% of 
obese individuals do not have metabolic abnormalities. The 
“healthy obese” appear to have less clustering of CVD risk Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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factors. What determines healthy obesity vs unhealthy obesity 
is unknown. In a study by Stefan et al80 subjects were divided 
into 3 groups – normal weight, obese-insulin sensitive, and 
obese-insulin resistant – and cardiovascular risk factors 
were examined. They found that the obese-insulin sensitive 
group had intimal medial thicknesses similar to that seen in 
the normal weight group, and when compared to the insulin 
resistant group, had less skeletal muscle fat, less hepatic fat 
deposits, and lower intimal-media thickness of the common 
carotid artery, giving them a more favorable risk profile 
despite similar weights. Thus, it appears that in some limited 
circumstances, the adipose tissue has a greater ability to 
expand without the associated metabolic stress that triggers 
pro-inflammatory cytokine production and downstream 
effects such as insulin resistance. Mitigating factors such as 
physical activity and genetic background may play a key role 
to the health of this small cohort of the obese population, and 
serve to remind us of the need for further understanding and 
possibly phenotyping of the obese patient.
Conclusion
Obesity is an abnormal state of chronic overnutrition and 
reduced physical activity with genetic predisposition play-
ing a role in worsening consequences and development of 
co-morbid conditions. Obesity is commonly associated with 
increased production of proinflammatory cytokines, insulin 
resistance, and changes in body fat distribution. In addition, 
there are multiple, complex, redundant biochemical pathways 
that have an impact locally and systemically to provoke and 
potentiate insulin resistance and chronic inflammation, which 
in turn promote further downstream perturbations such as 
DM, OSA, HTN and CVD. Thus, the ability to store and limit 
fatty acid deposition to adipose tissue is a key component 
in remaining insulin sensitive, controlling the inflammatory 
cascade, and reducing the risk of developing obesity-related 
comorbidities such as DM.
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